Piper Jaffray analyst Sean Wieland raised his price target for Teladoc to $77 after the company Q2 beat numbers and increased guidance. The analyst highlights Teladoc’s 39% organic growth driven by “continued strong” utilization and “solid M&A execution” that has accelerated BestDoctors. He keeps an Overweight rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.